CE Mogensen, ME Cooper - Diabetic Medicine, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 39 - Related articles - BL Direct - All 4 versions
- ►asnjournals.org KA Griffin, AK Bidani - Clinical Journal of the American Society of Nephrology, 2006 - Am Soc Nephrol Recent guidelines for management of patients with chronic kidney disease
recommend both lower optimal BP targets and agents that block the
renin-angiotensin system (RAS) for specific additional BP-independent ... Cited by 33 - Related articles - BL Direct - All 4 versions
KA Griffin, AK Bidani - Current hypertension reports, 2004 - Springer Investigations using chronic blood pressure (BP) radio- telemetry in conscious
animals have provided substantial insights into the pathophysiology of
hypertensive renal damage. Normal renal autoregulation protects the renal ... Cited by 18 - Related articles - BL Direct - All 3 versions
GS Hill, D Heudes, C Jacquot, E Gauthier, J … - Kidney international, 2006 - nature.com A morphometric study was performed on 22 renal biopsies from hypertensive
patients with proteinuria and/or azotemia, with no evidence of other renal
disease. These results were compared with our earlier study of normotensive ... Cited by 15 - Related articles - BL Direct - All 4 versions
LM Ruilope - Acta Diabetologica, 2005 - Springer Abstract Renal function is closely associated with cardiovascular risk, to the
extent that even minor renal abnormalities, which are present in 10% of the
general population, carry a greatly elevated risk of cardiovascular ... Cited by 12 - Related articles - All 2 versions
S Tobe - Current opinion in nephrology and hypertension, 2003 - journals.lww.com Purpose of review: The treatment of hypertension has been proven to reduce
cardiovascular and renal risk. The role of long-acting calcium channel
antagonists in the management of hypertension has been confused in the past ... Cited by 5 - Related articles - BL Direct - All 9 versions
KA Griffin, AK Bidani - Journal of Clinical Hypertension, 2006 - interscience.wiley.com Substantial evidence indicates that hypertension is a major contributor to the
development of end-stage renal disease in most patients. However, such risk
ranges from being fairly low in essential hypertension to a marked increase ... Cited by 4 - Related articles - All 2 versions
P Hovind - Danish Medical Bulletin, 2005 - dadlnet.dk Diabetes is the leading cause of end stage renal disease (ESRD) in the western
world, accounting for approximately 45% of patients with ESRD in the USA, and
25% of the patients with ESRD in Europe. Furthermore, the number of ... Cited by 1 - Related articles - Cached - All 3 versions
KJ Schjoedt, PK Christensen, A Jorsal, F … - Nephrology Dialysis Transplantation, 2009 - ERA-EDTA Results. During placebo, the mean (SE) basal GFR was 115 (5) ml/min/1.73 m 2 and
the BP was 146 (4)/81 (2) mmHg corresponding to a MAP of 103 (2) mmHg.
Spironolactone did not significantly reduce GFR or BP. Injection of ... Cited by 1 - Related articles - All 3 versions
KA Griffin, AK Bidani - Current Cardiology Reports, 2008 - Springer Antihypertensive therapy remains the most effective strat- egy for slowing the
progression of chronic kidney disease (CKD). However, in proteinuric
nephropathies, calcium channel blockers (CCBs) are less effective than ... Related articles - All 2 versions
